TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Remotely Delivered Episodic Future Thinking Intervention to Improve Management of Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Overweight or obese (BMI of 25 or greater)~* Poorly controlled type 2 diabetes (HbA1C of 8% or greater)~* Prescribed or recommended oral glucose-lowering medication~Exclusion Criteria:~* Current insulin therapy for type 2 diabetes~* History of gestational diabetes~* Pregnant or lactating~* Not ambulatory~* Intellectual impairment~* Unmanaged medical or psychiatric disorder~* Abnormal glucose related to medications (e.g, glucocorticoids)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Episodic future thinking (Type: EXPERIMENTAL): Participants will generate positive future events and related text cues that will be accessed via an electronic app to engage in episodic future thinking.
- Control thinking (Type: SHAM_COMPARATOR): Participants will generate non-future-oriented information and related text cues that will be accessed via an electronic app to engage in control thinking..

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women with osteoporosis~Exclusion Criteria:~* Any known allergy to the study drug

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hypertonic Saline as Add on Therapy in Preschool Children With Acute Wheezing Attack.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children, age: 1-6 years old~* Presenting to the ED with acute wheezing episode~Exclusion Criteria:~* Any chronic (lung, cardiac, immunologic, neurologic) disease

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Hypertonic saline-salbutamol combination (Type: ACTIVE_COMPARATOR): NaCl 5% - 4cc (with standard treatment - salbutamol 0.5cc)
- normal saline-salbutamol combination (Type: PLACEBO_COMPARATOR): Standard treatment normal saline 4cc with salbutamol 0.5cc

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥19 years~* receiving in-center hemodialysis two or more times weekly~* anemia requiring erythropoiesis stimulating (ESA) agent therapy OR a hemoglobin(Hb)\<100g/L in the absence of other causes of anemia~* if female, must be using an approved method of contraception or judged unable to become pregnant~* able to give informed consent~Exclusion Criteria:~* acute kidney injury likely to resolve~* plans to change to peritoneal dialysis or home hemodialysis, or planned transplant from a living donor~* expected lifespan of less than six months due to a medical condition other than chronic kidney disease~* current hematologic condition that may cause anemia~* use of medications known to cause anemia~* use of any investigational drug or androgen within 90 days of screening~* significant bleeding within 30 days of screening~* red blood cell transfusion(s) within 30 days of screening~* documented or suspected pure red cell aplasia (PRCA)~* current iron deficiency~* documented allergy or intolerance to intravenous sodium ferric gluconate~* known or probable ESA resistance~* uncontrolled hypertension~* an intention to relocate to a different dialysis center in the near future

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epoetin alfa (Type: ACTIVE_COMPARATOR): Patients who are enrolled and randomized to the Epoetin arm will remain on their current dose and frequency. After the first hemoglobin (Hb) measurement the study algorithm will be used to guide anemia management. The subjects in this arm will remain on epoetin for the required run-in phase followed by the 12 month active phase.
- Darbepoetin alfa (Type: ACTIVE_COMPARATOR): Patients who are enrolled and randomized to the Darbepoetin arm will have their epoetin discontinued at the end of the week preceding entry into the study and will switch to darbepoetin on the date that they would normally be receiving their next dose of epoetin.~Switching patients to darbepoetin will be done using the conversion ratio of 200 units of epoetin to 1 μg of darbepoetin as used per week, rounded up or down to the nearest available pre-filled syringe dose available from the manufacturer.~After the first Hb measurement the study algorithm will be used to guide anemia management. The subjects in this arm will remain on darbepoetin for the required run-in phase followed by the 12 month active phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexametasone Versus Dexametasone Plus Dexmedetomidine in Nerve Blocks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists classification 1-3~* Body mass index between 20 and 35~Exclusion Criteria:~* Adults who are unable to give their own consent~* Pre-existing neuropathy (assessed by history and physical examination)~* Coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets ≤ 100, International Normalized Ratio ≥ 1.4 or prothrombin time ≥ 50)~* Renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. creatinine ≥ 100)~* Hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. transaminases ≥ 100)~* Allergy to local anesthetics (LAs)~* Pregnancy~* Prior surgery in the infraclavicular region~* Chronic pain syndromes requiring opioid intake at home

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Perineural dexamethasone (Type: ACTIVE_COMPARATOR): Addition of dexamethasone 2mg to local anesthetics in infraclavicular brachial plexus block
- Perineural dexamethasone plus dexmedetomidine (Type: EXPERIMENTAL): Addition of dexamethasone plus dexmedetomidine to local anesthetics in infraclavicular brachial plexus block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 14.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women-not-of-childbearing potential diagnosed with type 2 diabetes for at least three months~* Stable treatment regimen with either metformin (at least 1500 mg) or diet and exercise alone for at least three months~* HbA1c: 7.0-10.0 % (both inclusive)~* Body weight between 60 kg and 110 kg~Exclusion Criteria:~* Treatment with insulin, GLP-1 receptor agonists (including liraglutide), dipeptidyl peptidase-4 inhibitors, sulphonylurea, thiazolidinediones, Alpha-GIs, or any investigational drug, within the last three months~* Impaired liver or kidney function~* Proliferative retinopathy or maculopathy requiring acute treatment~* Clinically significant active cardiovascular disease and uncontrolled treated/untreated hypertension~* Recurrent major hypoglycaemia or hypoglycaemic unawareness~* Present or planned use of any drug which could interfere with the glucose levels (e.g. systemic corticosteroids)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None
- C (Type: EXPERIMENTAL): None
- D (Type: EXPERIMENTAL): None
- E (Type: EXPERIMENTAL): None
- F (Type: EXPERIMENTAL): None
- G1 (Type: PLACEBO_COMPARATOR): None
- G2 (Type: PLACEBO_COMPARATOR): None
- G3 (Type: PLACEBO_COMPARATOR): None
- G4 (Type: PLACEBO_COMPARATOR): None
- G5 (Type: PLACEBO_COMPARATOR): None
- G6 (Type: PLACEBO_COMPARATOR): None
- H (Type: EXPERIMENTAL): None
- I (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Endoxifen in Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participant in the Karma Cohort~* Attending the national mammography screening program, i.e., aged 40-74 and have performed a screening mammogram maximum 3 months prior to study inclusion~* Mammographic density \~4.5 % density (volumetric) measured by Volpara, at the screening mammogram performed in connection to baseline (maximum 3 months prior to inclusion). The threshold value of 4.5% corresponds to the clinical Bl-RADS score A~* Postmenopausal, defined as no period of menstruation during last 12 months independent of any hormonal treatment~* Informed consent must be signed before any study specific assessments are performed~Exclusion Criteria:~* Any previous or current diagnosis of breast cancer (including carcinoma in situ).~* Any previous diagnosis of cancer with the exception of non-melanoma skin cancer and in situ cancer of the cervix.~* A history of major surgery of the breast, e.g., reduction or enlargement, which might affect density measurements.~* Mammographic Bl-RADS malignancy code 3, or above, at baseline mammography, or at mammography during time of treatment. Recall for additional examinations due to technical problems with the mammogram is accepted.~* Currently using estrogen and progesterone based hormone replacement therapy (oral or patches). Local estrogen treatment is accepted (ex. Vagifem).~* Non-medical approved drugs against hot-flashes including phytoestrogen.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Topical Placebo:Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
- Topical Endoxifen 10mg/breast/day (Type: ACTIVE_COMPARATOR): 10 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
- Topical Endoxifen 20mg/breast/day (Type: ACTIVE_COMPARATOR): 20 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Combination Therapies for Gonorrhea Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female from 15 - 60 years old.~* Is either:~  1. Untreated male or female with urethral or cervical gonorrhea as determined by a screening laboratory test \[either Nucleic Acid Amplification Test (NAAT) or culture\] for Neisseria gonorrhoeae at a prior visit.~ 2. Urethral or cervical gram stain demonstrating gram negative intracellular diplococci and leukocytes.~ 3. Untreated male or female who is a sexual contact (anal, oral, or vaginal) of an individual with gonorrhea in the past 60 days.~* Willing to abstain from anal, oral, or vaginal sexual intercourse or use condoms until follow up is completed.~* Willing to follow up from 10 to 17 days following enrollment.~* Willing to provide written consent.~* Able to swallow pills.~Exclusion Criteria:~* Known renal insufficiency from clinical history~* Known hepatic insufficiency from clinical history~* Known QT interval prolongation from clinical history~* Known neuromuscular disorder from clinical history (i.e., myasthenia gravis or Parkinson's disease)~* Known rheumatoid arthritis or tendon disorders from clinical history~* Known kidney, heart, or lung transplants from clinical history~* Pregnant women (determined by positive urine pregnancy test)~* Breastfeeding women~* Known allergy or adverse reaction to macrolides, aminoglycosides, or quinolones~* Concomitant infection (besides chlamydia or bacterial vaginosis) which requires systemic antibiotics~* Has received systemic or intravaginal antibiotics within 30 days of study enrollment~* Currently taking corticosteroid drugs or other immunosuppressive therapy~* Currently taking cardiac antiarrhythmia drugs~* Self report of or clinical diagnosis of abdominal pain, pelvic inflammatory disease (PID), testicular pain, epididymitis, or disseminated gonococcal infection~* Self report of or clinical diagnosis of current genital ulcer (GU)~* In the judgment of the interviewer, has a medical condition or other factor that might affect their ability to follow the protocol~* Previous enrollment in this study

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Regimen B: gemifloxacin plus azithromycin (Type: EXPERIMENTAL): Gemifloxacin 320 mg by mouth one time plus azithromycin 2 gm by mouth one time.
- Regimen A: gentamicin plus azithromycin (Type: EXPERIMENTAL): Gentamicin 240 mg intramuscular (IM) one time for patients greater than 45 kg or 5 mg/kg IM one time for patients less than or equal to 45 kg plus azithromycin 2 gm by mouth one time.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Usability of Diabetes Dashboard Embedded Within a Patient Web Portal

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes Mellitus~* Currently being treated with at least one antihyperglycemic medication~* Able to speak and read in English~* Have reliable access to a computer with internet access~* Existing My Health at Vanderbilt (i.e., patient portal) account~Exclusion Criteria:~* Living in long term care facilities~* Known cognitive deficits~* Severe visual or hearing impairment~* Unintelligible speech (e.g., dysarthria)~* Currently participating in another diabetes-related research study

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Patients have access to a patient web portal with the Patient-facing Diabetes Dashboard activated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Healthy subjects~* Body mass index (BMI) in the range of 18.0 - 32.0 kg/m2~Key Exclusion Criteria:~* Poor peripheral venous access~* Clinically-significant illness within 4 weeks of dose administration~* Active or acute infection requiring systemic antibiotic treatment within 2 weeks prior to Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- KPL-404 (IV Administration) (Type: EXPERIMENTAL): None
- KPL-404 (SC Administration) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Phase I portion:~* Relapsed or refractory acute myelogenous or lymphoid leukemia.~* Chronic myelogenous leukemia in accelerated phase or blast-crisis.~* Recurrent or refractory malignant lymphoma or Hodgkin's disease~* Recurrent or refractory multiple myeloma.~* Chronic lymphocytic leukemia, relapsed or with poor prognostic features.~* Myeloproliferative disorder (polycythemia vera, myelofibrosis) with transformation~* Myelodysplastic syndromes with more than 5% blasts.~Phase II portion:~* AML with active disease or beyond CR2.~* MDS with more than 5% blasts.~Exclusion Criteria:~* Clinical progression. Such patients may be treated on other treatment protocols or at the investigator's discretion. Such patients will continue to be monitored for survival and, may be asked to continue to provide specimens for studies of minimal residual disease and immune reconstitution as other treatments are recommended.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Busulfan and fludarabine (Type: EXPERIMENTAL): Intravenous busulfan (Busulfan®) in combination with fludarabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects 18 to 65 years of age.~* Body Mass Index (BMI) ≤ 33 kg/m2, and total body weight of 60 kg to 90 kg (132 lbs to 198 lbs).~* Fasting LDL-C must be \> 130 mg/dL (borderline high per NCEP ATP III criteria) at two qualifying visits: initial screening (Days -28 to -14) and Day -7.~Exclusion Criteria:~* Poorly controlled type 1 or type 2 diabetes mellitus (HbA1c \> 9.0%).~* History of a cardiovascular or cerebrovascular event (eg, MI, stroke, TIA) or related procedure (eg, angioplasty) during the past year.~* Subjects who meet the New York Heart Association (NYHA) criteria for congestive heart failure (CHF) classes III or IV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Single 150 mg PF-04950615 dose administered to the abdomen (Type: ACTIVE_COMPARATOR): None
- Single 150 mg PF-04950615 dose administered to the upper arm (Type: EXPERIMENTAL): None
- Single 150 mg PF-04950615 dose administered to the thigh (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete